Christophe Dubois, Tom Adriaenssens, Lieven Annemans, Johan Bosmans, Britt Callebaut, Pascal Candolfi, Kristoff Cornelis, Alexis Delbaere, Michelle Green, Joelle Kefer, Patrizio Lancellotti, Michael Rosseel, Judith Shore, Jan Van Der Heyden, Sebastian Vermeersch, Eric Wyffels
BACKGROUND: Transcatheter aortic valve implantation (TAVI) with the SAPIEN 3 device has recently shown significant clinical benefits, compared to surgical aortic valve replacement (SAVR), in patients at low risk for surgical mortality (PARTNER 3 trial, NCT02675114). Currently in Belgium, TAVI use is restricted to high-risk or inoperable patients with severe symptomatic aortic stenosis (sSAS). This cost-utility analysis aimed to assess whether TAVI with SAPIEN 3 could lead to potential cost-savings compared with SAVR, in the low-risk sSAS population in Belgium...
February 2024: Acta Cardiologica